Procedures/injectables require selection criteria — possible prior authorization

Submit claims using the listed CPT/HCPCS/ICD-10 codes only when the policy's selection criteria are met; certain interlaminar (62320–62327) and transforaminal epidural injection codes (64479, 64483) and injectable corticosteroid HCPCS (J1020–J2930 range) are covered when criteria are satisfied and may require prior authorization per plan procedures.

• Use CPT codes 62320–62327 for interlaminar epidural injections when selection criteria are met.
• Use CPT codes 64479 and 64483 for transforaminal epidural injections with imaging guidance (fluoroscopy or CT) as described.
• Bill appropriate HCPCS corticosteroid codes (J1020–J2930) only when policy selection criteria are documented.

Prior authorization note — clinician-applied capsaicin patch (Qutenza)

Qutenza (8% capsaicin patch) is a clinician-applied, procedure‑like therapy; if requested, prior authorization justification should document indication (PHN), adherence to application parameters, and prior therapies tried.

• Qutenza must be applied by a health care professional and is administered to the most painful areas (up to 4 patches; 60 minutes application).
• Document prior treatments and refractory status if payer requires prior authorization for topical high‑concentration capsaicin.

No explicit prior authorization specified in these excerpts

This excerpt does not specify concrete prior authorization codes or explicit plan PA rules; consult the Clinical Policy Bulletin Notes and member plan provisions for any plan‑specific PA requirements.

• No specific PA codes or mandates are present in these document chunks.
• Plan provisions or Clinical Policy Bulletin Notes may define PA processes for your patient.

Prior authorization justification — thoracic TF ESI: document prior therapy failures

For thoracic transforaminal epidural steroid injections used for refractory PHN, expect to provide documentation of failure of prior oral/topical medications and prior nerve/intercostal blocks plus baseline and follow-up pain scores to justify use.

• Record prior conservative treatments attempted (oral and topical agents) and any prior intercostal or peripheral nerve blocks.
• Include baseline and post-procedure pain assessments (e.g., VAS/NRS at 1 week and subsequent follow-ups).

Prior authorization justification — capsaicin 8% patch (Qutenza)

If payer prior authorization is required for high‑concentration (8%) capsaicin patch, justify with evidence of refractory neuropathic pain/PHN and documentation of prior therapy failure; observational series and cohorts form the primary evidence base referenced.

• Cite PHN diagnosis, baseline pain intensity (VAS/NRS), prior systemic and topical therapies, and response history.
• Note that evidence cited includes randomized trials for Qutenza and observational cohorts for other neuropathic pain populations.

No explicit prior authorization codes specified for CT/fluoroscopy-guided interventional studies

The document includes procedural descriptions performed under CT or fluoroscopic guidance but does not list concrete prior authorization codes for those interventional studies; verify plan PA requirements locally.

• Studies describe CT- or fluoroscopy-guided procedures (e.g., IVFO, DRG PRF + TFAESI) without specifying PA codes.
• Confirm with the member's plan whether PA is required and which codes apply.

Prior authorization referenced — consult Clinical Policy Bulletin Notes and plan provisions

The policy references Clinical Policy Bulletin Notes and plan provisions for administering benefits; providers should consult those resources for plan‑specific prior authorization rules and claiming requirements.

• Clinical Policy Bulletin Notes and member plan provisions may include PA requirements not present in this excerpt.
• Treating providers remain responsible for medical decisions and verifying benefit coverage.

Conservative‑first implied — document trials of first‑line therapies before invasive/experimental options

Conservative therapies (oral antivirals during acute HZ, tricyclic antidepressants, gabapentin, pregabalin, 5% lidocaine patch, opioids/tramadol) are identified as first‑line and are implied to be tried before higher‑risk or experimental interventions.

• Document trials of guideline‑recommended systemic agents prior to escalation.
• Intrathecal corticosteroids are noted as reserved for refractory cases and approached with caution.

Preferred first‑ and second‑line pharmacologic therapies — document trials of guideline agents

Preferred pharmacologic therapies endorsed in guideline summaries include tricyclic antidepressants, gabapentin, pregabalin, opioids, and lidocaine patch and should be used prior to considering less‑proven therapies.

• Ensure documentation of trial and response to TCAs, gabapentin/pregabalin, or lidocaine patch when applicable.
• Consider opioids only when guideline options are inadequate or contraindicated.

No formal step‑therapy sequence specified in this excerpt

No explicit step‑therapy sequencing or mandatory prior‑therapy durations are defined in this excerpt; the literature implies but does not mandate specific sequencing.

• Policy excerpts do not establish a formal step‑therapy algorithm or fixed trial durations.
• Providers should record reasonable trials of first‑line agents and clinical rationale for escalation.

Conservative pharmacologic trial expected before invasive interventions

Prior to invasive procedures such as DRG PRF or other nerve‑directed interventions, studies and the policy expect prior adequate trials of guideline‑recommended pharmacologic therapy (e.g., gabapentinoids) and documentation of inadequate response or intolerance.

• Document prior gabapentin/pregabalin use, dosing, duration, and reason for discontinuation or inadequate response.
• Record concomitant medications and any prior nerve block responses.

Document conservative therapy attempts prior to interventional procedures

Multiple interventional studies cited describe that patients had trials of conservative measures (anticonvulsants, antidepressants) before proceeding to interventional approaches; document these conservative therapy attempts when seeking authorization or billing.

• Record medications tried, duration, and objective pain scores showing inadequate response.
• Include rationale for escalation to interventional or topical high‑concentration therapies.

Document intolerance or inadequate response to gabapentinoids when used as study inclusion rationale

Some studies enrolled patients intolerant or insensitive to first‑line gabapentinoids before receiving CT‑guided ozone injections; when applicable, document intolerance or lack of efficacy to support use of less‑established interventions.

• Document objective evidence of intolerance (adverse effects) or insufficient analgesia to gabapentin/pregabalin.
• Include prior attempts at alternative first‑line agents if relevant.

Coding and documentation linkage — bill listed codes only with required selection criteria

Use the CPT/HCPCS/ICD-10 codes listed in the policy when submitting claims; covered codes require that the policy's selection criteria and clinical documentation be met to avoid denial.

• Match the billed CPT/HCPCS codes to the procedures performed and provide supporting clinical documentation per the policy.
• Covered CPT codes are only payable when selection criteria described in the policy are satisfied.

Qutenza — required procedural documentation (anesthetic, patch count, 60‑minute application, ≥1‑hour monitoring)

When performing Qutenza application, document topical anesthetic pretreatment, the number of patches applied (up to 4), 60‑minute application duration, and observe and record patient monitoring for at least 1 hour for blood pressure changes.

• Record who applied the patch (trained health care professional), topical anesthetic used, and any additional analgesic measures.
• Document monitoring data (BP) for at least 1 hour post‑application and any immediate adverse events.

No additional universal provider documentation requirements specified in these excerpts

This excerpt contains no general provider documentation mandates beyond procedure‑specific notes; follow plan benefit documentation requirements and Clinical Policy Bulletin Notes for any additional plan‑specific documentation.

• No universal documentation checklist is specified in these chunks.
• Providers retain responsibility for treatment decisions and should verify plan documentation expectations.

Required clinical documentation for interventional procedures (baseline/follow‑up pain scores and prior therapy details)

For interventional procedures document baseline pain scores (e.g., VAS/NRS), prior conservative treatments attempted, details of prior nerve blocks, and follow‑up pain assessments (1, 2, 4, 12 weeks) to support medical necessity and outcomes.

• Include detailed procedural reports, imaging guidance used, and objective pain measures pre‑ and post‑procedure.
• Record complications and subsequent medication changes during follow‑up visits.

Required clinical documentation for capsaicin 8% patch (diagnosis, baseline pain, prior therapies, responses)

Clinical documentation for capsaicin 8% patch use should include the diagnosis (PHN or peripheral neuropathic pain), baseline pain intensity (VAS/NRS), prior systemic and topical therapies tried, and responses to prior treatments.

• Document prior medication trials and whether capsaicin is used as add‑on or first‑line in the treatment plan.
• Record follow‑up pain scores and any adverse events such as high BP or local site reactions.

For procedural reports, record demographics, VAS scores, and complications at 1, 6, 12 months

Procedural reports in interventional studies commonly recorded demographics, VAS scores, and complications at 1, 6, and 12 months; include similar longitudinal data when claiming medical necessity for interventional approaches.

• Include demographic and clinical baseline data, procedure details, and long‑term pain and complication monitoring.
• Such documentation supports outcome assessment and potential continued authorization.

Denial risk — do not bill listed not‑covered procedures/codes for PHN indications

Claims for procedures or codes listed as not covered for indications in this policy (examples include pulsed radiofrequency of DRG, peripheral nerve stimulation, TENS devices/supplies, stellate ganglion block codes, neurostimulator implantation, extracorporeal shockwave code 0101T) may be denied when submitted for PHN.

• Do not submit claims for listed not‑covered CPT/HCPCS codes for PHN indications unless plan guidance indicates otherwise.
• Examples: PRF of DRG, TENS device/supplies (A4595, E0720, E0730), neurostimulator implantation (63650, 63655).

Qutenza application and monitoring — trained applicator, anesthetic, 60‑minute application, ≥1‑hour BP monitoring

Failure to have Qutenza applied by a trained health care professional, to follow application parameters (up to 4 patches, 60 minutes, repeat ≥3 months), or to monitor the patient for at least 1 hour for blood pressure rise after placement may conflict with product‑label procedures and the policy's application guidance.

• Ensure documented application by a trained clinician, topical anesthetic pretreatment, and BP monitoring for ≥1 hour post‑application.
• Repeat applications should not be performed more frequently than every 3 months per product labeling.

No other explicit authorization or billing denial triggers specified in these excerpts

No explicit provider authorization or billing denial triggers are stated in these excerpts beyond the not‑covered code lists; consult plan provisions for any additional denial risk factors.

• The document excerpts do not define other explicit billing denial triggers.
• Verify plan‑specific administrative rules for authorizations and denials.

Predictive value of poor early response to TF ESI (<50% at 1 week) — may affect continued authorization

A poor early response (<50% pain improvement) to an initial transforaminal epidural injection at 1 week predicted progression to PHN in a cited cohort and may influence decisions about continued interventions or authorization.

• Document 1‑week post‑injection pain improvement; <50% improvement is a potential predictor of progression to PHN.
• Use early response data to support clinical decisions about further interventions or authorization needs.

Safety concern — trigeminal ganglion/ophthalmic‑division blocks can cause neurotrophic keratopathy/visual changes; document consent and monitoring

Serious ocular adverse events (neurotrophic keratopathy, decreased visual acuity) have been reported after trigeminal (Gasserian) ganglion block; document informed consent, procedural details, and monitor for ocular complications when performing periorbital/ophthalmic‑division interventions.

• Obtain and document informed consent discussing potential ocular risks.
• Record imaging guidance used (fluoroscopy) and post‑procedure ocular assessments if applicable.

Investigational therapies — document limited evidence and prior therapy failure; no automatic coverage in these excerpts

Many interventional therapies described in these chunks are characterized as investigational or preliminary and no explicit authorization or coverage‑denial rules are provided here; larger well‑designed RCTs are needed before broader adoption.

• When recommending investigational interventions, document rationale, prior conservative therapy failure, and discuss limited evidence with the patient.
• Expect payers to require stronger evidence or case‑by‑case review for investigational procedures.

CPB advisory — consult plan benefits; CPBs do not guarantee coverage

Clinical Policy Bulletins assist in administering plan benefits but do not guarantee coverage; providers should verify member benefits and recognize they retain responsibility for medical decisions and treatment outcomes.

• Consult member plan provisions and Clinical Policy Bulletin Notes for coverage and authorization specifics.
• Providers are independent and responsible for clinical care; the CPB does not constitute a contract or coverage promise.